Clinically relevant treatment considerations regarding lithium use in bipolar disorder. (2nd November 2017)

• Record Type: Journal Article
• Authors: Richardson, Tara; Macaluso, Matthew
• Is Part Of: Expert opinion on drug metabolism and toxicology. Volume 13:Number 11(2017:Nov.)
• Page Start: 1105
• Page End: 1113
• Publication Date: 2017-11-02
• Subjects: Lithium -- mood stabilizer -- bipolar disorder -- mania -- bipolar depression -- drug-drug interactions -- pharmacodynamics -- pharmacokinetics; Drugs -- Toxicology -- Periodicals; Drugs -- Metabolism -- Periodicals; 615.7
• DOI: 10.1080/17425255.2017.1386653
• Languages: English
• ISSNs: 1742-5255

Abstract

ABSTRACT: Introduction : The goal of this paper is to provide a practical, clinically oriented review of lithium, a salt widely used to treat mania since the 1870s and formally approved as a mood stabilizer in 1970. Although lithium is still considered a first-line treatment for bipolar mania in most practice guidelines, its use may be overshadowed by newer psychotropic medications. Areas covered : This paper addresses the historical use of lithium, modern indications for its use, guidelines for prescribing and monitoring continued lithium use, drug-drug interactions, and pharmacodynamics/pharmacokinetic properties. The paper also reviews the unique properties of lithium and their potential clinical importance. Expert opinion : While the use of lithium does involve some unique risks to the patient, it may also has some unique advantages in certain patient populations. Two major findings that make lithium unique are its potential neuroprotective benefits and decreased risk of suicide in patients with mood disorders.